ATAGI Targeted Review 2021: the national COVID-19 vaccination program

Authors

  • Sanjay Jayasinghe National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
  • Cyra Patel National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory, Australia
  • Lucy Armstrong National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia
  • Clayton Chiu National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
  • Kristine Macartney National Centre for Immunisation Research and Surveillance, Children’s Hospital at Westmead, Sydney, New South Wales, Australia; Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia
  • Katie Flanagan Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia; Tasmanian Vaccine Trial Centre, Launceston General Hospital, Tasmania, Australia; School of Medicine, University of Tasmania, Tasmania, Australia; School of Health & Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, Victoria, Australia
  • Katherine Gibney Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; The Peter Doherty Institute for infection and Immunity, Melbourne, Victoria, Australia
  • Michelle Giles Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia; Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia
  • Nigel Crawford Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia; Immunisation Services, Royal Children’s Hospital, Melbourne, Victoria, Australia; Infection and Immunity, Murdoch Children’s Research Institute and Department Paediatrics, University of Melbourne, Victoria, Australia
  • Allen Cheng Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia; Monash Infectious Diseases, Monash Health and School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
  • Chris Blyth Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia; Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute and School of Medicine, University of Western Australia, Perth, Western Australia, Australia; Department of Infectious Diseases, Perth Children’s Hospital and PathWest Laboratory Medicine, Perth, Western Australia, Australia

DOI:

https://doi.org/10.33321/cdi.2023.47.20

Keywords:

COVID 19, vaccination, Australia

Abstract

The overarching goal of the Australian coronavirus disease 2019 (COVID-19) vaccination program has been to protect all people in Australia from the harm caused by the novel coronavirus SARS-CoV-2. This review reflects on the role of the Australian Technical Advisory Group on Immunisation (ATAGI) in the national COVID-19 vaccination program, in terms of the initial programmatic and clinical recommendations in the evolving context of evidence relating to the disease and vaccines, epidemiology, and the program rollout. To fulfil the obligation to provide evidence-based advice to the Minister for Health and Aged Care on the safe, effective and equitable use of COVID-19 vaccines, ATAGI has worked closely with other agencies and committees such as the Therapeutic Goods Administration (TGA) and the Communicable Diseases Network Australia. ATAGI recommendations have sought to optimise the use of the available vaccine doses in achieving the objectives of preventing serious illness and death from COVID-19 while addressing any emerging safety signals following program commencement on 22 February 2021. As of mid-November 2021, the use of COVID-19 vaccines in children aged 5 to 11 years was being considered by the TGA and ATAGI; and emerging evidence, in areas such as use of heterologous vaccine schedules and co-administration with other vaccines, was under review. Despite unprecedented challenges which the delivery of mass COVID-19 vaccination presented to health systems globally, in Australia much was achieved in 2021 with over 90% coverage for primary doses in the vaccine-eligible population. Evaluation, using high quality data and assessment methods, of vaccination program outcomes—such as coverage, vaccine effectiveness and impact—is key to determine whether program objectives have been achieved and where gaps remain. Reflecting on the lessons learned so far would help further improve the national COVID-19 vaccination program and would also benefit programs for other routine vaccines and planning for future pandemics.

Downloads

Download data is not yet available.

References

International Labour Organisation (ILO), Foods and Agricultural Organisation (FAO), International Fund For Agricultural Development (IFAD), World Health Organization (WHO). Impact of COVID-19 on people’s livelihoods, their health and our food systems. [Internet.] Geneva: WHO; 13 October 2020. [Accessed on 27 September 2021.] Available from: https://www.who.int/news/item/13-10-2020-impact-of-covid-19-on-people%27s-livelihoods-their-health-and-our-food-systems.

Emanuel EJ, Persad G, Kern A, Buchanan A, Fabre C, Halliday D et al. An ethical framework for global vaccine allocation. Science. 2020;369(6509):1309–12. doi: https://doi.org/10.1126/science.abe2803.

Australian Government Department of Health and Aged Care. Government response to the COVID-19 outbreak. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/government-response-to-the-covid-19-outbreak.

Vanderslott S, Dadonaite B, Roser M. Vaccintation: Vaccine Innovation. [Online resource.] Oxford: University of Oxford, Our World In Data; 2021. [Accessed on 27 October 2021.] Available from: https://ourworldindata.org/vaccination#vaccine-innovation.

Australian Technical Advisory Group on Immunisation (ATAGI). Preliminary advice on general principles to guide the prioritisation of target populations in a COVID-19 vaccination program in Australia. Canberra: Australian Government Department of Health and Aged Care, ATAGI; November 2020. Available from: https://www.health.gov.au/sites/default/files/documents/2020/11/atagi-preliminary-advice-on-general-principles-to-guide-the-prioritisation-of-target-populations-in-a-covid-19-vaccination-program-in-australia_0.pdf.

Australian Government Department of Health and Aged Care. The COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group. Meetings. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 29 November 2021.] Available from: https://www.health.gov.au/committees-and-groups/the-covid-19-vaccines-and-treatments-for-australia-science-and-industry-technical-advisory-group#meetings.

Australian Government Department of Health and Aged Care. Australia’s COVID-19 Vaccine and Treatment Strategy. Canberra: Australian Government Department of Health and Aged Care; 18 August 2020. [Accessed on 29 November 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2020/08/australia-s-covid-19-vaccine-and-treatment-strategy.pdf.

Australian Government Department of Health and Aged Care. Aboriginal and Torres Strait Islander Advisory Group on COVID-19. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 17 August 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/committees-and-groups/aboriginal-and-torres-strait-islander-advisory-group-on-covid-19.

Australian Government Department of Health and Aged Care. Culturally and Linguistically Diverse Communities COVID-19 Health Advisory Group. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/committees-and-groups/culturally-and-linguistically-diverse-communities-covid-19-health-advisory-group.

Australian Government Department of Health and Aged Care. Advisory Committee for the COVID-19 Response for People with Disability. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/committees-and-groups/advisory-committee-for-the-covid-19-response-for-people-with-disability.

Australian Government Department of Health and Aged Care. Aged Care Advisory Group. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 20 September 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/committees-and-groups/aged-care-advisory-group.

Australian Government Department of Health and Aged Care. Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi-covid-19-working-group.

WHO. WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Geneva: WHO; 13 September 2020. Available from: https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination.

National Academies of Sciences Engineering and Medicine. Framework for Equitable Allocation of COVID-19 Vaccine. Washington, DC: The National Academies Press; 2020. [Accessed on 20 September 2021.] Available from: https://www.nap.edu/read/25917/chapter/1.

New South Wales State Government. Report. Special Commission of Inquiry into the Ruby Princess. Sydney: New South Wales State Government; 14 August 2020. [Accessed on 20 September 2021.] Available from: https://apo.org.au/sites/default/files/resource-files/2020-08/apo-nid307566.pdf.

Gidding HF, Machalek DA, Hendry AJ, Quinn HE, Vette K, Beard FH et al. Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020. Med J Aust. 2021;214(4):179–85. doi: https://doi.org/10.5694/mja2.50940.

Coatsworth N, Myles PS, Mann GJ, Cockburn IA, Forbes AB, Gardiner EE et al. Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: a prospective surveillance study. ANZ J Surg. 2021;91(1–2):27–32. doi: https://doi.org/10.1111/ans.16564.

Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He JS et al. A dual-antigen enzyme-linked immunosorbent assay allows the assessment of severe acute respiratory syndrome coronavirus 2 antibody seroprevalence in a low-transmission setting. J Infect Dis. 2021;223(1):10–4. doi: https://doi.org/10.1093/infdis/jiaa623.

Viray P, Low Z, Sinnappu R, Harvey PA, Brown S. Residential aged care facility COVID-19 outbreaks and magnitude of spread among residents: observations from a Victorian residential in-reach service. Intern Med J. 2021;51(1):99–101. doi: https://doi.org/10.1111/imj.15143.

Victoria State Government Department of Health and Human Services (DHHS). Coronavirus update for Victoria - 31 October 2020. [Internet.] Melbourne: Victoria State Government, DHHS; 31 October 2020. Available from: https://www.dhhs.vic.gov.au/coronavirus-update-victoria-31-october-2020.

Quigley AL, Stone H, Nguyen PY, Chughtai AA, MacIntyre CR. Estimating the burden of COVID-19 on the Australian healthcare workers and health system during the first six months of the pandemic. Intern J Nurs Stud. 2021;114:103811. doi: https://doi.org/10.1016/j.ijnurstu.2020.103811.

Australian Government Department of Health and Aged Care. COVID-19 vaccination – ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021. [Online resource.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 20 September 2021.] Available from: https://www.health.gov.au/resources/publications/covid-19-vaccination-atagi-clinical-guidance-on-covid-19-vaccine-in-australia-in-2021.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi: https://doi.org/10.1056/NEJMoa2034577.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi: https://doi.org/10.1016/S0140-6736(20)32661-1.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–16. doi: https://doi.org/10.1056/NEJMoa2035389.

ModernaTX Inc, Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases. A study to evaluate efficacy, safety, and immunogenicity of mRNA- 1273 vaccine in adults aged 18 years and older to prevent COVID-19. ClinicalTrials.gov identifier: NCT04470427. [Webpage.] Bethesda: United States National Library of Medicine; 31 July 2020. [Accessed on 12 August 2021.] Available from: https://clinicaltrials.gov/ct2/show/NCT04470427.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–93. doi: https://doi.org/10.1016/S0140-6736(20)32466-1.

European Medicines Agency (EMA). COVID-19 Vaccine AstraZeneca: Product Information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission. Amsterdam: EMA; 29 January 2021. [Accessed on 26 April 2021.] Available from: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf.

Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. doi: https://doi.org/10.1056/NEJMoa2107456.

Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Eng J Med. 2021;385(24):2241–51. doi: https://doi.org/10.1056/NEJMoa2109522.

ATAGI. COVID-19 vaccination – Provider resources: Guidance to help people make informed decisions. [Webpage.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 2021. [Accessed on 1 Octover 2021.] Available from: https://www.health.gov.au/resources/collections/covid-19-vaccination-provider-resources#guidance-to-help-people-make-informed-decisions.

EMA. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks - Update. [Internet.] Amsterdam: EMA; 11 March 2021. [Accessed on 13 October 2021.] Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits.

EMA. COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria. [Internet.] Amsterdam: EMA; 10 March 2021. [Accessed on 13 October 2021.] Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-preliminary-view-suggests-no-specific-issue-batch-used-austria.

ATAGI. ATAGI statement and clinical guidance on AstraZeneca COVID-19 vaccine following European Medicines Agency (EMA) safety review. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 19 March 2021. Available from: https://www.health.gov.au/news/atagi-statement-and-clinical-guidance-on-astrazeneca-covid-19-vaccine-following-european-medicines-agency-ema-safety-review.

EMA. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. [Internet.] Amsterdam: EMA; 18 March 2021. [Accessed on 28 September 2021.] Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.

ATAGI. ATAGI statement for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 25 March 2021. [Accessed on 27 September 2021.] Available from: https://www.health.gov.au/news/atagi-statement-for-health-care-providers-on-suitability-of-covid-19-vaccination-in-people-with-history-of-clotting-conditions.

Therapeutic Goods Administration (TGA). Specific clotting condition reported after COVID-19 vaccination. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 2 April 2021. [Accessed on 13 October 2021.] Available from: https://www.tga.gov.au/media-release/specific-clotting-condition-reported-after-covid-19-vaccination.

ATAGI. ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 8 April 2021. [Accessed on 25 September 2021.] Available from: https://www.health.gov.au/news/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns.

Winton Centre for Risk and Evidence Communication (Winton Centre). Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine. Cambridge: University of Cambridge, Winton Centre; 2021. [Accessed on 13 October 2021.] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/976877/CovidStats_07-04-21-final.pdf.

Australian Government Department of Health and Aged Care. Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca: Information for health care providers to help consumers make informed decisions. Canberra: Australian Government Department of Health and Aged Care; 29 June 2021. [Accessed on 25 September 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/06/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca_2.pdf.

ATAGI, Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ). A joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca.[Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI, THANZ; 23 May 2021. [Accessed on 13 October 2021.] Available from: https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca.

ATAGI. ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 17 June 2021. [Accessed on 26 September 2021.] Available from: https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021.

Joint Committee on Vaccination and Immunisation (JCVI). JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021. [Internet.] London: Unted Kingdom Government, Department of Health and Social Care; 7 April 2021. [Accessed on 18 November 2021.] Available from: https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021.

National Advisory Committee on Immunization (NACI). Archived 8: NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults [2021-03-29]. [Internet.] Ottawa: Government of Canada, Health Canada, NACI; 29 March 2021. [Accessed on 18 November 2021.] Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommended-use-astrazeneca-covid-19-vaccine-younger-adults.html.

European Centre for Disease Prevention and Control (ECDC). Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. 18 May 2021. Solna: ECDC; 18 May 2021. [Accessed on 18 November 2021.] Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Overview%20EU%20EEA%20country%20recommendations%20on%20COVID-19%20vaccination%20Vaxzevria%20and%20scoping%20review%20of%20evidence.pdf.

Australian Government Department of Health and Aged Care. Sentiment Towards COVID-19 Vaccine Research. Canberra: Australian Government Department of Health and Aged Care; April 2021. [Accessed on 15 November 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/08/foi-request-2398-release-documents-covid-19-vaccine-market-research-sentiment-towards-covid-19-vaccine-research-april-2021-part-1.pdf.

Essential Report. Essential Report: Preference towards COVID-19 vaccines (summary of results published 3 August 2021). Melbourne: Esential Media Communications; 3 August 2021. [Accessed on 13 October 2021.] Available from: https://essentialvision.com.au/preference-towards-covid-19-vaccines-4.

ATAGI. ATAGI statement on use of COVID-19 vaccines in an outbreak setting. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 13 July 2021. [Accessed on 13 October 2021.] Available from: https://www.health.gov.au/news/atagi-statement-on-use-of-covid-19-vaccines-in-an-outbreak-setting.

ATAGI. ATAGI Statement, Response to NSW COVID-19 outbreak 24th July 2021. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 24 July 2021. [Accessed on 13 October 2021.] Available from: https://www.health.gov.au/news/atagi-statement-response-to-nsw-covid-19-outbreak-24th-july-2021.

Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. [Preprint.] The Global Health Network; 2021. Available from: https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf.

Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977–82. doi: https://doi.org/10.15585/mmwr.mm7027e2.

ATAGI, Cardiac Society of Australia and New Zealand (CSANZ). COVID-19 vaccination – Guidance on Myocarditis and Pericarditis after mRNA COVID-19 vaccines. Canberra: Australian Government Department of Health and Aged Care, ATAGI, CSANZ; 30 July 2021. [Accessed on 27 September 2021.] Available from: https://www.health.gov.au/resources/publications/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines.

TGA. TGA Provisional Approval of Pfizer-BioNTech COVID-19 vaccine to include 12–15 years age group. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 23 July 2021. [Accessed on 13 October 2021.] Available from: https://www.tga.gov.au/tga-provisional-approval-pfizer-biontech-covid-19-vaccine-include-12-15-years-age-group.

ATAGI. ATAGI statement regarding vaccination of adolescents aged 12–15 years. [Internet.] Canberra: Australian Government Department of Health and Aged Care, ATAGI; 2 August 2021. [Accessed on 25 September 2021.] Available from: https://www.health.gov.au/news/atagi-statement-regarding-vaccination-of-adolescents-aged-12-15-years.

ATAGI. ATAGI recommendations on the use of COVID-19 vaccines in all young adolescents in Australia. Canberra: Australian Government Department of Health and Aged Care, ATAGI; 27 August 2021. [Accessed on 27 September 2021.] Available from: https://www.health.gov.au/news/atagi-recommendations-on-the-use-of-covid-19-vaccines-in-all-young-adolescents-in-australia.

TGA. TGA provisionally approves Moderna’s COVID-19 vaccine. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 9 August 2021. [Accessed on 13 October 2021.] Available from: https://www.tga.gov.au/media-release/tga-provisionally-approves-modernas-covid-19-vaccine.

TGA. TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 4 September 2021. [Accessed on 13 October 2021.] Available from: https://www.tga.gov.au/media-release/tga-provisional-approval-moderna-covid-19-vaccine-include-12-17-years-age-group.

Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout update – 30 September 2021. Canberra: Australian Government Department of Health and Aged Care; 30 September 2021. Available from: https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-30-september-2021.

Australian Government Department of Health and Aged Care. COVID-19 vaccination – Australian COVID-19 Vaccination Policy. Canberra: Australian Government Department of Health and Aged Care; 13 November 2020. Available from: https://www.health.gov.au/resources/publications/covid-19-vaccination-australian-covid-19-vaccination-policy.

Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout update – 31 July 2021. Canberra: Australian Government Department of Health and Aged Care; 31 July 2021. Available from: https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-31-july-2021.

ATAGI. ATAGI statement on considerations for establishing drive-through COVID-19 vaccination clinic sites. [Internet.] Canberra: Australian Government Depatment of Health and Aged Care, ATAGI; 9 August 2021. [Accessed on 28 September 2021.] Available from: https://www.health.gov.au/news/atagi-statement-on-considerations-for-establishing-drive-through-covid-19-vaccination-clinic-sites.

Therapeutic Goods Administration (TGA). TGA approves more flexible storage conditions for Pfizer-BioNTech COVID-19 vaccine. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA; 24 May 2021. [Accessed on 28 September 2021.] Available from: https://www.tga.gov.au/behind-news/tga-approves-more-flexible-storage-conditions-pfizer-biontech-covid-19-vaccine.

Australian Government Department of Health and Aged Care. COVID-19 vaccination daily rollout update. [Website.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 28 September 2021.] Available from: https://www.health.gov.au/resources/collections/covid-19-vaccination-daily-rollout-update.

Australian Government Department of Health and Aged Care. COVID-19 vaccine rollout update – 30 November 2021. Canberra: Australian Government Department of Health and Aged Care; 30 November 2021. [Accessed on 5 December 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/11/covid-19-vaccine-rollout-update-30-november-2021.pdf.

Centers for Disease Control (CDC). CDC Statement on ACIP Booster Recommendations. [Internet.] Atlanta: United States Department of Health and Human Services, CDC; 24 September 2021. Available from: https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html.

JCVI. Independent report: Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination. [Internet.] London: Unted Kingdom Government, Department of Health and Social Care; 1 September 2021. [Accessed on 28 September 2021.] Available from: https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination.

Andrews N, Tessier E, Stowe J, Gower G, Kirsebom F, Simmons R et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340–50. doi: https://doi.org/10.1056/NEJMoa2115481.

de Gier B, Kooijman M, Kemmeren J, de Keizer N, Dongelmans D, van Iersel SCJL et al. COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April–August 2021. medRxiv. 2021. doi: https://doi.org/10.1101/2021.09.15.21263613.

Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–16. doi: https://doi.org/10.1016/S0140-6736(21)02183-8.

Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions — United States, March–August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(38):1337–43. doi: https://doi.org/10.15585/mmwr.mm7038e1.

Hadjadj J, Planas D, Ouedrani A, Buffier S, Delage L, Nguyen Y et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022. doi: https://doi.org/10.1136/annrheumdis-2021-221508.

Haidar G, Agha M, Bilderback A, Lukanski A, Linstrum K, Troyan R et al. Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVicS). Clin Infect Dis. 2022;75(1):e630–44. doi: https://doi.org/10.1093/cid/ciac103.

Kearns P, Siebert S, Willicombe M, Gaskell C, Kirkham A, Pirrie S et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE trial. [Internet.] Amsterdam: Elsevier, SSRN; 23 August 2021. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3910058.

Caillard S, Chavarot N, Bertrand D, Kamar N, Taunat O, Moal V et al. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 2021;100(2):477–9. doi: https://doi.org/10.1016/j.kint.2021.05.011.

Wadei HM, Gonwa TA, Leoni JC, Shah SZ, Aslam N, Speicher LL. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination. Am J Transplant. 2021;21(10):3496–9. doi: https://doi.org/10.1111/ajt.16618.

Whitaker H.J, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Pillai PS et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. J Infect. 2022. doi: https://doi.org/10.1016/j.jinf.2021.12.044.

Young-Xu Y, Korves C, Roberts J, Powell EI, Zwain GM, Smith J et al. Coverage and estimated effectiveness of mRNA SARS-CoV-2 vaccines among US veterans. JAMA Netw Open. 2021;4(10):e2128391. doi: https://doi.org/10.1001/jamanetworkopen.2021.28391.

Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021;161(3):827–36. doi: https://doi.org/10.1053/j.gastro.2021.05.044.

Chemaitelly H, AlMukdad S, Joy JP, Ayoub HH, Yassine HM, Benslimane FM et al. SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients. medRxiv. 2021. doi: https://doi.org/10.1101/2021.08.07.21261578.

Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis. 2021;23(5):e13705. doi: https://doi.org/10.1111/tid.13705.

ATAGI. Recommendations on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised. Version 1.0 7 October 2021. Canberra: Australian Government Department of Health and Aged Care, ATAGI; 7 October 2021. [Accessed on 27 October 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/10/atagi-recommendations-on-the-use-of-a-third-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised_1.pdf.

Australian Government Department of Health and Aged Care, Minister for Health and Aged Care. Start of COVID-19 booster vaccination program. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 8 November 2021. [Accessed on 18 November 2021.] Available from: https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/start-of-covid-19-booster-vaccination-program.

ATAGI. Australian Technical Advisory Group on Immunisation (ATAGI) recommendations on the use of a booster dose of COVID-19 vaccine. Canberra: Australian Government Department of Health and Aged Care, ATAGI; 27 October 2021. [Accessed on 18 November 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/10/atagi-recommendations-on-the-use-of-a-booster-dose-of-covid-19-vaccine.pdf.

Callaway E. Mix-and-match COVID vaccines trigger potent immune response. Nature. 2021;593(7860):491. doi: https://doi.org/10.1038/d41586-021-01359-3.

Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. The Lancet. 2021;397(10289):2043–6. doi: https://doi.org/10.1016/S0140-6736(21)01115-6.

CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States: interchangeability of COVID-19 vaccine products. [Internet.] Atlanta: United States Department of Health and Human Services, CDC: 2021. [Accessed on 27 October 2021.] Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Interchangeability.

NACI. Archive 22: Recommendations on the use of COVID-19 vaccines [2021-10-22]. [Internet.] Ottawa: Government of Canada, Health Canada, NACI; 22 October 2021. [Accessed on 27 October 2021.] Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html.

ATAGI. Statement on the administration of seasonal influenza vaccines in 2021 – updated June 2021. Canberra: Australian Government Department of Health and Aged Care, ATAGI; June 2021. [Accessed on 27 October 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/06/atagi-advice-on-seasonal-influenza-vaccines-in-2021.pdf.

CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States : coadministration of COVID-19 vaccines with other vaccines. [Internet.] Atlanta: United States Department of Health and Human Services, CDC: 2021. [Accessed on 27 October 2021.] Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Coadministration.

Public Health England. COVID-19 – SARS-CoV-2. London: United Kingdom Government; 2021. [Accessed on 27 October 2021.] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1018444/Greenbook_chapter_14a_16Sept21.pdf.

Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(2)167–79. doi: https://doi.org/10.1016/S2213-2600(21)00409-4.

Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277–87. doi: https://doi.org/10.1016/S0140-6736(21)02329-1.

Janssen Vaccines & Prevention BV. A study of Ad26.COV2.S and influenza vaccines in healthy adults. ClinicalTrials.gov identifier: NCT05091307. [Webpage.] Bethesda: United States National Library of Medicine; 25 October 2021. [Accessed on 27 October 2021.] Available from: https://clinicaltrials.gov/ct2/show/NCT05091307.

Sanofi Pasteur. Study of a quadrivalent high-dose influenza vaccine and a Moderna COVID-19 vaccine administered either concomitantly or singly in participants 65 years of age and older previously vaccinated with a 2-dose schedule of Moderna COVID-19 vaccine. ClinicalTrials.gov identifier: NCT04969276. [Webpage.] Bethesda: United States National Library of Medicine; 20 July 2021. [Accessed on 27 October 2021.] Available from: https://clinicaltrials.gov/ct2/show/NCT04969276.

Pfizer. Safety and immunogenicity study of 20vPnC when coadministered with a booster dose of BNT162b2. ClinicalTrials.gov identifier: NCT04887948. [Webpage.] Bethesda: United States National Library of Medicine; 14 May 2021. [Accessed on 27 October 2021.] Available from: https://clinicaltrials.gov/ct2/show/ NCT04887948.

United States Food and Drug Administration (FDA). FDA News Release: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. [Internet.] Silver Spring: United States Department of Health and Human Services, FDA; 29 October 2021. [Accessed on 18 November 2021.] Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.

Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1)35–46. doi: https://doi.org/10.1056/NEJMoa2116298.

ModernaTX Inc. A study to evaluate safety and effectiveness of mRNA-1273 COVID-19 vaccine in healthy children between 6 months of age and less than 12 years of age. ClinicalTrials.gov identifier: NCT04796896. [Webpage.] Bethesda: United States National Library of Medicine; 15 March 2021. [Accessed on 1 October 2021.] Available from: https://clinicaltrials.gov/ct2/show/NCT04796896.

University of Oxford. Oxford COVID-19 vaccine study in children - FAQs. [Internet.] Oxford: University of Oxford; 2021. [Accessed on 1 October 2021.] Available from: https://covid19vaccinetrial.co.uk/faqs-childrens-trial.

Cherian T, Hwang A, Mantel C, Veira C, Malvolti S, MacDonald N et al. Global Vaccine Action Plan lessons learned III: monitoring and evaluation/accountability framework. Vaccine. 2020;38(33):5379–83. doi: https://doi.org/10.1016/j.vaccine.2020.05.028.

Australian National Audit Office (ANAO). Australia’s COVID-19 Vaccine Rollout. [Webpage.] Canberra: ANAO; 2022. [Accessed on 25 January 2022.] Available from: https://www.anao.gov.au/work/performance-audit/australia-covid-19-vaccine-rollout.

Parliament of Australia: House of Representatives. BILLS – Australia Immunisation Register Amendment (Reporting) Bill 2020 – Second Reading. [Hansard transcript.] Canberra: Parliament of Australia; 3 December 2020. Available from: https://www.aph.gov.au/Parliamentary_Business/Hansard/Hansard_Display?bid=chamber/hansardr/11b18738-de56-4d82-82f6-2c10fddd6b2b/&sid=0019.

Australian Government Operation COVID Shield. Op COVID Shield: National COVID Vaccine Campaign Plan. 3 August 2021. Canberra: Australian Government; 3 August 2021. [Accessed on 18 November 2021.] Available from: https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-national-covid-vaccine-campaign-plan.pdf.

Downloads

Published

27/04/23

How to Cite

Jayasinghe, Sanjay, Cyra Patel, Lucy Armstrong, Clayton Chiu, Kristine Macartney, Katie Flanagan, Katherine Gibney, et al. 2023. “ATAGI Targeted Review 2021: The National COVID-19 Vaccination Program”. Communicable Diseases Intelligence 47 (April). https://doi.org/10.33321/cdi.2023.47.20.

Issue

Vol. 47 (2023)

Section

Review article

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>